Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome

Registry ID

EUCTR2009-013667-19

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Novartis Pharma Services AG

Start date

2010-10-15

Completion date

2013-08-14

Last update

2026-08-16

Conditions

• Fragile X Syndrome
• Síndrome X Frágil

Summary

To assess the efficacy of three doses of AFQ056 versus placebo in reducing the ABC-C Total score (using the FXS specific algorithm - ABC-CFX) after 12 weeks of treatment in FXS patients with fully-methylated FMR1 gene.

Locations

• , , Denmark
• , , Italy
• , , Spain
• , , UK
• , , Germany

Related clinical trials

• Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
• Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
• Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome
• Parent and Infant Inter(X)Action Intervention (PIXI)
• Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant
• Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

View on source registry